Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Eur J Cancer
2022 Jul 01;170:285-295. doi: 10.1016/j.ejca.2022.04.005.
Show Gene links
Show Anatomy links
Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER.
Joshua AM
,
Armstrong A
,
Crumbaker M
,
Scher HI
,
de Bono J
,
Tombal B
,
Hussain M
,
Sternberg CN
,
Gillessen S
,
Carles J
,
Fizazi K
,
Lin P
,
Duggan W
,
Sugg J
,
Russell D
,
Beer TM
.
???displayArticle.abstract???
BACKGROUND: Statins and metformin are commonly prescribed for patients, including those with prostate cancer. Preclinical and epidemiologic studies of each agent have suggested anti-cancer properties.
METHODS: Patient data from three randomised, double-blind, placebo-controlled, phase III studies evaluating enzalutamide (AFFIRM, PREVAIL and PROSPER) in patients with castration-resistant prostate cancer were included in this analysis. This post hoc, retrospective study examined the association of statin and metformin on radiographic progression-free survival (rPFS), metastasis-free survival (MFS), toxicity and overall survival (OS). After adjusting for available clinical prognostic variables, multivariate analyses were performed on pooled data from AFFIRM and PREVAIL, all three trials pooled, and each trial individually, to assess differential efficacy in these end-points associated with the baseline use of these medications.
RESULTS: In the multivariate analysis of the individual trials, OS and rPFS/MFS were not significantly influenced by statin or metformin use in AFFIRM or PROSPER. However, in PREVAIL, OS was significantly influenced by statin (hazard ratio [HR] 0.72; 95% confidence interval [CI] 0.59-0.89) and rPFS was significantly influenced by metformin (HR, 0.48; 95% CI 0.34-0.70). In pooled analyses, improved OS was significantly associated with statin use but not metformin use for AFFIRM+PREVAIL trials (HR 0.83; 95% CI 0.72-0.96) and AFFIRM+PREVAIL+PROSPER (HR 0.75; 95% CI 0.66-0.85).
CONCLUSIONS: The association between statin or metformin use and rPFS, MFS and OS was inconsistent across three trials. Analyses of all three trials pooled and AFFIRM+PREVAIL pooled revealed that statin but not metformin use was significantly associated with a reduced risk of death in enzalutamide-treated patients. Additional prospective, controlled studies are warranted.
CLINICAL TRIAL REGISTRATION: AFFIRM (NCT00974311), PREVAIL (NCT01212991) and PROSPER (NCT02003924).
???displayArticle.pubmedLink???
35643841
???displayArticle.link???Eur J Cancer ???displayArticle.grants???[+]
Alghandour,
Repurposing metformin as anticancer drug: Randomized controlled trial in advanced prostate cancer (MANSMED).
2021, Pubmed
Alghandour,
Repurposing metformin as anticancer drug: Randomized controlled trial in advanced prostate cancer (MANSMED).
2021,
Pubmed
Anderson-Carter,
The impact of statins in combination with androgen deprivation therapyin patients with advanced prostate cancer: A large observational study.
2019,
Pubmed
Armstrong,
ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.
2019,
Pubmed
Armstrong,
Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial.
2020,
Pubmed
Beer,
Enzalutamide in metastatic prostate cancer before chemotherapy.
2014,
Pubmed
Beer,
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study.
2017,
Pubmed
Bensimon,
The use of metformin in patients with prostate cancer and the risk of death.
2014,
Pubmed
Halabi,
Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer.
2009,
Pubmed
Halabi,
Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy.
2013,
Pubmed
Halabi,
Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer.
2014,
Pubmed
Hankinson,
A review for clinicians: Prostate cancer and the antineoplastic properties of metformin.
2017,
Pubmed
Hoque,
Statin induces apoptosis and cell growth arrest in prostate cancer cells.
2008,
Pubmed
Hussain,
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.
2018,
Pubmed
Iacovelli,
The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer.
2018,
Pubmed
Kochuparambil,
Anticancer efficacy of simvastatin on prostate cancer cells and tumor xenografts is associated with inhibition of Akt and reduced prostate-specific antigen expression.
2011,
Pubmed
Larsen,
Postdiagnosis Statin Use and Mortality in Danish Patients With Prostate Cancer.
2017,
Pubmed
Li,
Comorbidities and Concomitant Medication Use in Men with Prostate Cancer or High Levels of PSA Compared to Matched Controls: A GPRD Analysis.
2012,
Pubmed
Liu,
Metformin Inhibits Prostate Cancer Progression by Targeting Tumor-Associated Inflammatory Infiltration.
2018,
Pubmed
Liu,
Metformin reverses prostate cancer resistance to enzalutamide by targeting TGF-β1/STAT3 axis-regulated EMT.
2017,
Pubmed
Mikkelsen,
Associations between statin use and progression in men with prostate cancer treated with primary androgen deprivation therapy.
2017,
Pubmed
Rothermundt,
Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09).
2014,
Pubmed
Schalken,
Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer.
2016,
Pubmed
Scher,
Increased survival with enzalutamide in prostate cancer after chemotherapy.
2012,
Pubmed
Scher,
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
2008,
Pubmed
Shore,
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.
2020,
Pubmed
Spratt,
Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality.
2013,
Pubmed
Sternberg,
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.
2020,
Pubmed
Stopsack,
Metformin and prostate cancer mortality: a meta-analysis.
2016,
Pubmed
Wang,
Metformin inhibits metastatic breast cancer progression and improves chemosensitivity by inducing vessel normalization via PDGF-B downregulation.
2019,
Pubmed
Wang,
Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor.
2015,
Pubmed
Whitburn,
Metformin and Prostate Cancer: a New Role for an Old Drug.
2017,
Pubmed
Winters,
Metformin effects on biochemical recurrence and metabolic signaling in the prostate.
2015,
Pubmed
